These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 30219580)

  • 21. Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys.
    Dang UJ; Ziemba M; Clemens PR; Hathout Y; Conklin LS; ; Hoffman EP
    Hum Mol Genet; 2020 Aug; 29(15):2481-2495. PubMed ID: 32592467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The corticosteroid compounds prednisolone and vamorolone do not alter the nociception phenotype and exacerbate liver injury in sickle cell mice.
    Almeida LEF; Damsker JM; Albani S; Afsar N; Kamimura S; Pratt D; Kleiner DE; Quezado M; Gordish-Dressman H; Quezado ZMN
    Sci Rep; 2018 Apr; 8(1):6081. PubMed ID: 29666400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vamorolone improves Becker muscular dystrophy and increases dystrophin protein in
    McCormack NM; Nguyen NY; Tully CB; Oliver T; Fiorillo AA; Heier CR
    iScience; 2023 Jul; 26(7):107161. PubMed ID: 37534133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy.
    Finanger E; Vandenborne K; Finkel RS; Lee Sweeney H; Tennekoon G; Yum S; Mancini M; Bista P; Nichols A; Liu H; Fretzen A; Donovan JM
    J Neuromuscul Dis; 2019; 6(1):43-54. PubMed ID: 30452422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit.
    Sreetama SC; Chandra G; Van der Meulen JH; Ahmad MM; Suzuki P; Bhuvanendran S; Nagaraju K; Hoffman EP; Jaiswal JK
    Mol Ther; 2018 Sep; 26(9):2231-2242. PubMed ID: 30166241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prednisolone in Duchenne muscular dystrophy.
    Rahman MM; Hannan MA; Mondol BA; Bhoumick NB; Haque A
    Bangladesh Med Res Counc Bull; 2001 Apr; 27(1):38-42. PubMed ID: 11692899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study.
    Voit T; Topaloglu H; Straub V; Muntoni F; Deconinck N; Campion G; De Kimpe SJ; Eagle M; Guglieri M; Hood S; Liefaard L; Lourbakos A; Morgan A; Nakielny J; Quarcoo N; Ricotti V; Rolfe K; Servais L; Wardell C; Wilson R; Wright P; Kraus JE
    Lancet Neurol; 2014 Oct; 13(10):987-96. PubMed ID: 25209738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vamorolone treatment improves skeletal muscle outcome in a critical illness myopathy rat model.
    Akkad H; Cacciani N; Llano-Diez M; Corpeno Kalamgi R; Tchkonia T; Kirkland JL; Larsson L
    Acta Physiol (Oxf); 2019 Feb; 225(2):e13172. PubMed ID: 30120816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vamorolone, a dissociative steroidal compound, reduces pro-inflammatory cytokine expression in glioma cells and increases activity and survival in a murine model of cortical tumor.
    Wells E; Kambhampati M; Damsker JM; Gordish-Dressman H; Yadavilli S; Becher OJ; Gittens J; Stampar M; Packer RJ; Nazarian J
    Oncotarget; 2017 Feb; 8(6):9366-9374. PubMed ID: 28030841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.
    Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; Smith EC; McDonald CM; Zaidman CM; Morgenroth LP; Osaki H; Satou Y; Yamashita T; Hoffman EP;
    JAMA Neurol; 2020 Aug; 77(8):982-991. PubMed ID: 32453377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy.
    Escolar DM; Buyse G; Henricson E; Leshner R; Florence J; Mayhew J; Tesi-Rocha C; Gorni K; Pasquali L; Patel KM; McCarter R; Huang J; Mayhew T; Bertorini T; Carlo J; Connolly AM; Clemens PR; Goemans N; Iannaccone ST; Igarashi M; Nevo Y; Pestronk A; Subramony SH; Vedanarayanan VV; Wessel H;
    Ann Neurol; 2005 Jul; 58(1):151-5. PubMed ID: 15984021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial.
    Finkel RS; Finanger E; Vandenborne K; Sweeney HL; Tennekoon G; Shieh PB; Willcocks R; Walter G; Rooney WD; Forbes SC; Triplett WT; Yum SW; Mancini M; MacDougall J; Fretzen A; Bista P; Nichols A; Donovan JM
    Neuromuscul Disord; 2021 May; 31(5):385-396. PubMed ID: 33678513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy.
    Connolly AM; Schierbecker J; Renna R; Florence J
    Neuromuscul Disord; 2002 Dec; 12(10):917-25. PubMed ID: 12467746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant human insulin-like growth factor-1 therapy for 6 months improves growth but not motor function in boys with Duchenne muscular dystrophy.
    Rutter MM; Wong BL; Collins JJ; Sawnani H; Taylor MD; Horn PS; Backeljauw PF
    Muscle Nerve; 2020 May; 61(5):623-631. PubMed ID: 32108355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Corticosteroids in Duchenne muscular dystrophy: a reappraisal.
    Wong BL; Christopher C
    J Child Neurol; 2002 Mar; 17(3):183-90. PubMed ID: 12026233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy.
    Alman BA; Raza SN; Biggar WD
    J Bone Joint Surg Am; 2004 Mar; 86(3):519-24. PubMed ID: 14996877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: results of a double-blind randomized clinical trial.
    Flanigan KM; Voit T; Rosales XQ; Servais L; Kraus JE; Wardell C; Morgan A; Dorricott S; Nakielny J; Quarcoo N; Liefaard L; Drury T; Campion G; Wright P
    Neuromuscul Disord; 2014 Jan; 24(1):16-24. PubMed ID: 24321374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms and Clinical Applications of Glucocorticoid Steroids in Muscular Dystrophy.
    Quattrocelli M; Zelikovich AS; Salamone IM; Fischer JA; McNally EM
    J Neuromuscul Dis; 2021; 8(1):39-52. PubMed ID: 33104035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
    Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D
    Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Open Label Exploratory Clinical Trial Evaluating Safety and Tolerability of Once-Weekly Prednisone in Becker and Limb-Girdle Muscular Dystrophy.
    Zelikovich AS; Joslin BC; Casey P; McNally EM; Ajroud-Driss S
    J Neuromuscul Dis; 2022; 9(2):275-287. PubMed ID: 35124660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.